Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Positive predictive value of respiratory infection diagnoses in the Danish National Patient Registry: A post hoc validation analysis of the DANFLU-1 trial.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to Charlson Comorbidity Index: A post-hoc analysis of the DANFLU-1 randomized trial.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026
Same author

High-Dose vs Standard-Dose Influenza Vaccine in Older Adults With Diabetes: A Secondary Analysis of the DANFLU-2 Randomized Clinical Trial.

JAMA internal medicine·2026
Same author

Excess morbidity and mortality associated with seasonal influenza in patients with atrial fibrillation.

Heart rhythm·2026
Same author

A Bayesian re-analysis of the DANFLU-1 trial.

Human vaccines & immunotherapeutics·2026
Same author

High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease: The DANFLU-2 Trial Subgroup Analysis.

Journal of the American College of Cardiology·2025

Related Experiment Videos

[Psoriasis and atherothrombotic disease].

Ole Ahlehoff1, Gunnar H Gislason, Lone Skov

  • 1Kardiologisk Afdeling P, Gentofte Hospital, 2900 Hellerup, Denmark.

Ugeskrift for Laeger
|July 27, 2010
PubMed
Summary

Psoriasis patients have higher cardiovascular risks due to shared inflammation. Early assessment and treatment of cardiovascular disease in psoriasis patients are crucial.

Area of Science:

  • Immunoinflammatory mechanisms
  • Cardiovascular disease
  • Dermatology

Context:

  • Psoriasis is linked to increased cardiovascular risk factors.
  • Shared inflammatory pathways connect psoriasis and atherosclerosis.
  • Patients with psoriasis exhibit higher prevalence of hypercholesterolemia, hypertension, obesity, metabolic syndrome, and diabetes mellitus.

Purpose:

  • To review evidence linking psoriasis and cardiovascular disease.
  • To highlight the excess cardiovascular risk in psoriasis patients.
  • To advocate for improved cardiovascular risk assessment and management in psoriasis care.

Summary:

  • Psoriasis and atherosclerosis share common immunoinflammatory pathways.
  • Patients with psoriasis often have multiple cardiovascular risk factors.

Related Experiment Videos

  • Atherothrombotic disease risk is elevated in individuals with psoriasis.

    • Impact:

    • Increased awareness of cardiovascular risks in psoriasis patients.
    • Promotes proactive cardiovascular risk assessment and management.
    • Aims to reduce the burden of cardiovascular disease in the psoriasis population.